论文部分内容阅读
目的:探讨孟鲁司特对毛细支气管炎患儿血清白三烯D4和尿白三烯E4水平的影响。方法:选择毛细支气管炎患儿72例,随机分为实验组和对照组各36例。两组患儿均予以止咳化痰、解痉平喘和抗病毒等常规治疗,实验组在此基础上加用孟鲁司特咀嚼片2.5 mg,每天1次,连用7 d,比较两组患儿治疗前后血清白三烯D4和尿白三烯E4水平的变化,并进行临床疗效及安全性分析。结果:治疗7 d后,两组患儿血清白三烯D4和尿白三烯E4水平均较治疗前均明显下降(P<0.05或P<0.01),且实验组下降比对照组更明显,两组比较差异有统计学意义(P<0.05);实验组患儿临床总有效率94.44%,明显高于对照组的75.00%(χ2=5.26,P<0.05);对照组和实验组患儿治疗期间分别出现不良反应2例和4例(χ2=0.18,P>0.05),症状较轻,未出现严重药物不良反应。结论:孟鲁司特治疗婴幼儿毛细支气管炎疗效确切,安全性较佳,作用机制与降低血清白三烯D4和尿白三烯E4水平,减少白三烯的释放密切相关。
Objective: To investigate the effect of montelukast on serum leukotriene D4 and urinary leukotriene E4 in children with bronchiolitis. Methods: 72 children with bronchiolitis were randomly divided into experimental group and control group with 36 cases each. The two groups of children were given routine cough and phlegm, antispasmodic and anti-asthma and other conventional therapy, the experimental group on this basis with Montelukast chewable tablets 2.5 mg, once daily for 7 days, compared with two groups of children treated Before and after serum leukotriene D4 and urinary leukotriene E4 levels, and clinical efficacy and safety analysis. Results: Serum levels of leukotriene D4 and urinary leukotriene E4 in both groups were significantly lower than those before treatment (P <0.05 or P <0.01) after 7 days of treatment, and the decline in the experimental group was more obvious than that in the control group. The total clinical effective rate was 94.44% in the experimental group, which was significantly higher than that in the control group (75.00%, χ2 = 5.26, P <0.05). In the control group and the experimental group, there was significant difference between the two groups During treatment, adverse reactions occurred in 2 cases and 4 cases (χ2 = 0.18, P> 0.05), mild symptoms, no serious adverse drug reactions. Conclusion: Montelukast treatment of infantile bronchiolitis is effective and safe, and its mechanism of action is closely related to the reduction of serum leukotriene D4 and urinary leukotriene E4 levels and the reduction of leukotriene release.